KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Free Cash Flow: 2017-2025

Historic Free Cash Flow for Amneal Pharmaceuticals (AMRX) over the last 8 years, with Sep 2025 value amounting to $106.2 million.

  • Amneal Pharmaceuticals' Free Cash Flow fell 14.96% to $106.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $264.3 million, marking a year-over-year decrease of 0.71%. This contributed to the annual value of $243.2 million for FY2024, which is 19.57% down from last year.
  • Amneal Pharmaceuticals' Free Cash Flow amounted to $106.2 million in Q3 2025, which was up 74.05% from $61.0 million recorded in Q2 2025.
  • Amneal Pharmaceuticals' Free Cash Flow's 5-year high stood at $136.4 million during Q1 2021, with a 5-year trough of -$130.6 million in Q2 2022.
  • In the last 3 years, Amneal Pharmaceuticals' Free Cash Flow had a median value of $69.7 million in 2023 and averaged $64.3 million.
  • As far as peak fluctuations go, Amneal Pharmaceuticals' Free Cash Flow crashed by 175.95% in 2022, and later skyrocketed by 462.39% in 2023.
  • Amneal Pharmaceuticals' Free Cash Flow (Quarterly) stood at $45.8 million in 2021, then slumped by 175.95% to -$34.8 million in 2022, then skyrocketed by 462.39% to $126.0 million in 2023, then declined by 18.29% to $102.9 million in 2024, then declined by 14.96% to $106.2 million in 2025.
  • Its last three reported values are $106.2 million in Q3 2025, $61.0 million for Q2 2025, and -$5.8 million during Q1 2025.